Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-0100
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study ; day:28 ; month:9 ; year:2020 ; pages:1-10
Endocrine ; (28.9.2020), 1-10
- Creator
-
Kuhn, Emmanuelle
Caron, Philippe
Delemer, Brigitte
Raingeard, Isabelle
Lefebvre, Hervé
Raverot, Gérald
Cortet-Rudelli, Christine
Desailloud, Rachel
Geffroy, Clementine
Henocque, Robin
Brault, Yves
Brue, Thierry
Chanson, Philippe
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12020-020-02501-3
- URN
-
urn:nbn:de:101:1-2020121908570300099543
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kuhn, Emmanuelle
- Caron, Philippe
- Delemer, Brigitte
- Raingeard, Isabelle
- Lefebvre, Hervé
- Raverot, Gérald
- Cortet-Rudelli, Christine
- Desailloud, Rachel
- Geffroy, Clementine
- Henocque, Robin
- Brault, Yves
- Brue, Thierry
- Chanson, Philippe
- SpringerLink (Online service)
Other Objects (12)
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Acromegaly
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Acromegaly
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience